Embleema

Embleema

Created using Figma
Created using Figma

最後の更新

2018/10/31

あなたの病歴は改ざん防止であり、ブロックチェーンのデータセキュリティと配布機能のおかげで常に利用可能です どの病院があなたの病歴のどの部分を見ることができ、いつ誰にアクセスしたのかを正確に知ることができます あなたのプライバシーは、HIPAAに準拠した方法で完全に保護されています。
リスク:非常に高い
Private Sale
10月, 2018
3月, 2019
100% 完成した
資金調達 - データなし
309
ゴール 20 000 000.00 USD
キャップ 2 000 000.00 USD
硬質キャップ 30 000 000.00 USD
past
  • 1 RWD
    =
    0.2 USD
トークンの詳細
ティッカー
RWD
許容通貨
ETH, BTC, BCH, FIAT
会社の詳細
登録会社名
Embleema Inc
登録国
United States, France
設立された会社
Jun 1, 2017
追加の詳細
MVP /プロトタイプ
はい
プラットフォーム
Ethereum
KYC
はい
カテゴリー
健康

約 Embleema

Embleemaについて

Blockchainの技術は、患者、医療従事者、保険加入者、医療提供者、医療提供者に、患者の病歴を共有し、包括的で、縦長かつ信頼できる視点で提供できる理想的な基準であると考えています。取引の元帳として保存されている場合、患者の医療履歴には、患者の正当な承認を得てすべてのステークホルダーが明確にアクセスでき、最良の治療オプションを決定できます。

PatientTruth™病院、プライマリケアプラクティス、リハビリテーションセンター、介護施設、緊急ケアセンターなどのさまざまな医療サービスセンターで患者のさまざまな医療記録に接続し、それらを一貫性のある一貫性のある方法で結びつけるクラウドおよびブロックチェーンベースのソフトウェアソリューションです。包括的で、改ざんのない医療履歴を提供します。 PatientTruth™医療提供者や医療センター全体で患者の病歴を全体的に把握することができます。

特徴

Patients can:

• Register and sign-on through the Patient Dapp interface,

• Upload their health records in the Blockchain, • Visualize their patient record,

• Authorize the sharing of their identified patient record to providers,

• Expose and sell their health records in the Marketplace against RWE tokens,

• Visualize a full audit-trail on their patient record access and health records sold,

• Visualize a statement of his/her RWE transactions.

 

Providers can:

• Register and sign-on through the Provider Dapp interface,

• Visualize an identified patient record, with due consent from the patient,

• Perform a health record quality check, when requested by the health record data owner,

• Visualize a statement of his/her RWE transactions,

 

Care Centers and other Data Owners can:

• Register and sign-on through the Data Owner Dapp interface,

• Have their health records indexed into the Blockchain and linked to patients,

• Expose and sell their health records in the Marketplace against RWE tokens, with due consent from the patients,

• Visualize a statement of RWE transactions,

 

Pharma companies, Payers and other Data Buyers can:

• Register and sign-on through the Data Buyer Dapp interface,

• Expose their inclusion criteria for health record purchases,

• Browse a list of data owners which own health records matching their inclusion criteria,

• Select the data owners they wish to purchase health records from,

• Execute the purchase in RWE tokens with data owners,

• Visualize a statement of RWE transactions,

 

Pharma companies and authorities can:

• Register and sign-on through the Real-World Evidence Dapp interface,

• Pharma companies register health products on which they wish to share with authorities Real-World Evidence, and define the patient records they wish to share,

• Authorities can visualize the shared Real-World Evidence from Pharma companies.

We expect Version 2 to be HIPAA compliant (see “Embleema and Privacy Compliance section” below) for the U.S. users and GDPR compliant for the European users. Version 2 will include health records from U.S. patients. Version 2 is planned to launch in Q3 2019.

技術情報

Embleema Health Blockchainバージョン2には次の機能があります。


•患者の同意を管理するヘルスケア特有のスマート契約、
健康記録の保存、患者記録の保存と共有(特定および/特定不可)、患者記録アクセス監査証跡および
マーケットプレース、
•トランザクション料金およびその他の報酬のためにBlockchainによって生成された組み込みのRWEトークン。 RWEトークン取引では、送信者からの< />ガス料金の支払いは不要であり、予測可能なマイニング時間があります。
•健康記録のためのHL 7 FHIR、
CCD、独自の接続機器フォーマット、その他の健康記録フォーマットなど、さまざまなデータフォーマット入力をブロックチェーンに統合するためのAPIおよび健康記録パーサー。 >•スケーラビリティ:米国市場で最大200万人の患者。
•パフォーマンス:健康記録の視覚化は2秒以内に行い、ブロックチェーンでのマイニングは5秒以内に行います。
マーケットプレイスでのデータ購入者とデータ所有者の包含基準の調整
は1分以内に行う必要がありますデータソースの解析やインデックス作成などの他のバッチ処理は、各データソースのパフォーマンスの観点から評価されます。

ネットワーク参加者に公開されているスマートコントラクトは次のとおりです。
•健康記録:ブロックチェーンで健康記録を書いたり読んだりします。
•患者記録:特定の患者に健康記録を関連付け、ブロックチェーンから
患者記録を読みます。
•患者の同意:患者の健康記録(特定および非特定)を共有するための患者の承認を定義します。
•監査証跡:データ所有者に、自分の健康記録へのアクセス
に関する監査証跡を提供します。
•マーケットプレイス:患者からの適切な承認の後、データ所有者の健康記録メタデータ
を公開し、データ購入者が購入のために健康記録を検索することを可能にし、データ購入者と一致します。データ所有者レコードを含む包含基準
、データ購入者とデータ所有者との間で購入取引を実行します。

• RWEトークンのスマートコントラクト:ブロックチェーンに健康記録を保存するための
データ所有者への報酬としてRWEトークンを発行します(最初の3年間)

%name%ロードマップ

  • Embleema’s growth plan

  • Embleema has already launched the first patient Blockchain.

    Version 1 is publicly accessible at https://patienttruth.embleema.com
    and contains the following functionalities:
    • Upload HL7 Continuity of Care Documents (CCD) medical records
    into blockchain by patients (U.S. patients only),
    • Upload of Fitbit information into blockchain by patients,
    • Consolidation of CCDs (U.S. patients only) and Fitbit information
    into a Medical history stored securely on blockchain,
    • Authorization management from patients for the sharing of their
    Medical history with providers,
    • Visualization by providers of patients’ Medical histories after due
    authorization from patients,
    • Audit-trail for patients of Medical history accesses by providers,
    • Compensation to patients in EBL tokens for uploading CCDs
    (U.S. patients only) and Fitbit information, as well as referrals of
    new patients and providers.

    Version 1 will be used to pilot and prove in real-life the relevance of
    the 2 key concepts carried by the Embleema Health Blockchain:
    • Patients have control of their health records and may share and
    sell their data to pharma companies: this pilot will start in September
    2018 with cysticfibrosis.com, a U.S. based patient community in
    Cystic Fibrosis (announced on July 17, 2018: https://medcitynews.
    com/2018/07/embleema-emerges-from-stealth-mode-launchesblockchain-
    based-health-record-system/),
    • Pharma companies and regulators share the next generation of
    RWE: real-time, individual-patient level 360 view medical histories,
    with continuous monitoring of the same patient and his/her full
    and trusted consent: this pilot will start in January 2019 with
    a top-5 global pharma company and a leading health regulator
    (announcement planned in Q4 2018).
  • End of 2019

  • End of 2019, Embleema expects to expand its Blockchain to the French
    market and the China marketplace with its 800 million connected patient
    population by striking a set of strategic distribution partnerships with major
    local players in the healthcare and technology industry.
  • Q3 2019

  • Concurrently to its V2 launch in Q3 2019, Embleema plans to set up consulting
    services for pharmaceuticals and health network to facilitate the
    adoption of blockchain in their processes and systems.
  • 2021

  • In 2021, Embleema plans to launch V3 of its Health Blockchain Network
    which will able to integrate mining nodes from pharma companies, payers
    and care centers. V3 will also implement an API allowing third party patient
    app providers to connect to the Blockchain and offer personalized services
    to patients through the Blockchain.
  • 続きを読む
  • 2022

  • For 2022, with a critical mass of patient records stored onto the Blockchain,
    Embleema plans to offer advanced analytics services for various purposes:
    population health, observational studies, safety studies. Embleema will also
    start researching the possibility of offering predictive medicine services
    based on the wealth of data stored in the Blockchain.

アクティビティ

アクティビティ:
36
VERY LOW
投稿:
12
VERY LOW
ビュー:
450
VERY LOW
アクティビティ:
36
VERY LOW
値する:
0
VERY LOW
投稿:
12
VERY LOW
ビュー:
450
VERY LOW
ユーザー:
7
VERY LOW
フォロワー:
2 547
MEDIUM
ツイート:
487
HIGH
30日間の成長:
-4

Embleema チーム

検証済み 100%

Robert Chu
Founder, CEO and CTO
検証済み
Prashant Khambekar,...
Chief Blockchain Development Executive
検証済み
Pradeep Sreekanthan
Chief Delivery Officer
検証済み
Vincent Galand
Manager, Operations
検証済み
Pascal Becache
Business Development Executive
検証済み
Nicolas Schmidt
Chief Product Officer
検証済み
Alexis Normand
Head of Blockchain Consortium
検証済み

顧問

検証済み 29%

注意。確認されていないメンバーは実際にチームのメンバーではないというリスクがあります

Vahan Simonyan, PhD
Advisor | Chief Scientist - WHISE-Embleema Health...
未確認
Frederic Duchesne, P...
Advisor | CEO of Pierre Fabre Pharmaceuticals
未確認
Atakan Seçkin
Advisor | User Experience
検証済み
Pr. John Halamka, MD
Advisor | Professor of Innovation at Harvard Medic...
未確認
Adel Al-Saleh
Advisor | CEO of T-Systems and Board Member of Deu...
未確認
Bernard Gilly, PhD
Advisor | CEO at GenSight Biologics & Chairman at...
未確認
Lorenzo Nardiello
Social Media Manager
検証済み

Embleema インタビュー

Atakan Seçkin
As a team member, сan you tell us about your role in the ICO project?
Branding, UI/UX design and implementation of PatientTruth (since POC to product launch) ICO dashboard and future projects
What do you think about idea?
I've designed several products in healthcare industry prior to this project, and none of those projects placed the patient in the center - information asymmetry is a real problem. I believe blockchain with thoughtful design can enable patients to do so much more with their data - not only in terms of being aware, but also the control to choose who can see your data, and monetize it on your own terms and no one else's. We know we have a long road ahead, but I have confidence that we have the best team in the world to be making this product, and we can evolve it in a way that will disrupt existing industries.
Lorenzo Nardiello
As a team member, сan you tell us about your role in the ICO project?
I am in charge of the social media : Telegram, Bitcointalk, Reddit, Discord ... I also organize the bounty program that will come soon and manage our ambassador.
What do you think about idea?
Imagine a world in which you can contribute to medical research and create safer, less expensive and faster new treatments against cancer and rares diseases. Imagine a tamper-proof, holistic, longitudinal and patient-centric worldwide health record interfacing with medical researchers, health regulators, physicians, care centers and the pharmaceutical industry.
Robert Chu
As a team member, сan you tell us about your role in the ICO project?
Founder and CEO of Embleema
I am responsible for overall product strategy, go-to-market and sales of our Embleema Health Blockchain which was launched publicly in July 2018
What do you think about idea?
Embleema Health Blockchain helps patients to advance clinical research by securely sharing their data to pharmaceutical companies during real-world evidence and clinical trial studies. Pharmaceutical companies benefit from faster and more precise data which they can in turn share with regulators such as the U.S. Food and Drug Administration (FDA). Ultimately, patients receive innovative treatments sooner, this is the meaning of our work.
Prashant Khambekar, PhD
As a team member, сan you tell us about your role in the ICO project?
I handle the blockchain development. This includes the ICO/token part.

I also help determine the strategy of the company and its products.
What do you think about idea?
It is a wonderful idea whose time has come. Patients should have the right to control their own health data. The token mechanism helps maintain third-party oversight into the Embleema products.
Pradeep Sreekanthan
As a team member, сan you tell us about your role in the ICO project?
Delivering different versions of the platform. Making the customer experience delightful and easy. Working with various teams.
What do you think about idea?
Revolutionary - bringing healthcare to the blockchain is unusual and will be quite disruptive. RWE in particular.
Vincent Galand
As a team member, сan you tell us about your role in the ICO project?
I am Ops Manager at Embleema Inc. and run Embleema’s ICO operations, coordinating the team of technical experts, legal advisors, social media marketing manager and contractors around the project. I am also developping the business in Europe with pharma companies.
What do you think about idea?
I believe blockchain’s decentralisation power will disrupt the healthcare industry allowing everyone to participate to the advancement of medical progresses. Moreover, we developped a real, concrete industrial use case of Blockchain technology to accelerate medical research, e.g. Real World Evidence / Phase IV clinical trials. We are the only ICO project with a product already available on the market (PatientTruth), first major clients (Pierre Fabre, Servier, others coming soon) and a full support from the medical research community, the pharmaceutical industry and patient associations.
Pascal Becache
As a team member, сan you tell us about your role in the ICO project?
In France and Europe : Investors relations, business development, relations with Pharma companies. As a former IBM and IMS Health executive, I unveil the value of the patient data blockchain for investors, pharmaceutical companies, public and private health insurances and regulators.
What do you think about idea?
Embleema is the future of medical, drugs and population health studies. It will disintermediate collection and use of health data, allowing more, faster, cheaper and more ethical and transparent research benefiting to patients and healthcare systems. It complies with all regulatory aspects in the countries they enter.
Nicolas Schmidt
As a team member, сan you tell us about your role in the ICO project?
I'm Chief Product Officer at Embleema: I lead of our next product development, translate users and customers' needs into a world-class product and manage our marketing.
What do you think about idea?
We're the only healthcare project with a blockchain solution in production, valuable data on usage, several pharma companies as customers and a team of world-class advisors. We achieved all of this before launching our ICO in order to reduce risks for potential subscribers.
Alexis Normand
As a team member, сan you tell us about your role in the ICO project?
I bring together patient advocacy groups & life sciences researchers and regulatoirs to create a decentralized marketplace for health data, to replace the slow, manual and costly process of collecting real world evidence (RWE) for late stage clinical research
What do you think about idea?
Allowing patients to opt-in to pharma research along their own terms is game changing. Only blockchain allows patients to assemble the full picture of their health data, own and share it, and be compensated for their active involvement in clinical research.

Embleema 最後のニュース

  • 情報の更新には時差がある可能性があるため、各ICOプロジェクトに関する正確な情報は、公式Webサイトまたはその他の通信チャネルを通じて検証する必要があります。
  • この情報は、ICO資金への投資に関する提案やアドバイスではありません。関連情報を自分で徹底的に調査し、ICOの参加を決定してください。
  • このコンテンツに関して修正すべき問題や問題があると思われる場合、またはご自身のICOプロジェクトをリストに載せたい場合は、電子メールでご連絡ください。
免責事項とリスクに関する警告をお読みください。 免責事項とリスクの警告を表示します。
    

免責事項&リスクの警告     

このオファーは、オファーと他の一般に公開されている情報によってのみ提供される情報に基づいています。トークンの販売または交換のイベントは、ICOholderとは全く無関係であり、ICOholderはそれに関与していません(技術サポートやプロモーションを含む)。 ICOholderとの関係がない人物からのトークンの売り上げは、顧客が全体のトークンセクター内で行われている活動を追跡するのを助けるためにのみ表示されます。この情報は、あなたが頼りにするべきアドバイスにはなりません。弊社サイトのコンテンツに基づいて、行動を取る、または控える前に、プロフェッショナルまたはスペシャリストの助言を得るか、またはお客様のデューデリジェンスを実施する必要があります。トークンの取得に関してコントリビュータによって入力された条件は、トークンの発行者とトークンの発行者であり、ICOholderはそのようなトークンの販売者ではありません。 ICOholderは、トークンの販売に関して第三者が行ったいかなる表明についても法的責任を負いません。また、契約違反の申し立ては、ここに記載されたトークン発行会社に対して直接行われなければなりません。     

このトークン販売の性質、妥当性または合法性について懸念がある場合は、 [email protected] までご連絡ください。あなたの懸念事項に関する詳細情報と一緒に。

Planning an ICO? We can help with a wide range of support for all stages of your ICO